Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · February 28, 2013

First-Line Bendamustine + Rituximab vs CHOP + Rituximab in Indolent and Mantle-Cell Lymphomas

The Lancet

 

Additional Info

The Lancet
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment for Patients With Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised, Phase 3 Non-Inferiority Trial
Lancet 2013 Feb 20;[EPub Ahead of Print], MJ Rummel, N Niederle, G Maschmeyer, et al

Further Reading